181 related articles for article (PubMed ID: 35872510)
1. Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials.
Salawu A; Hernando-Calvo A; Chen RY; Araujo DV; Oliva M; Liu ZA; Siu LL
Eur J Cancer; 2022 Sep; 173():167-177. PubMed ID: 35872510
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.
Sweis RF; Drazer MW; Ratain MJ
J Clin Oncol; 2016 Feb; 34(4):369-74. PubMed ID: 26668350
[TBL] [Abstract][Full Text] [Related]
3. Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer.
Cook D; Biancalana M; Liadis N; Lopez Ramos D; Zhang Y; Patel S; Peterson JR; Pfeiffer JR; Cole JA; Antony AK
Front Artif Intell; 2023; 6():1153083. PubMed ID: 37138891
[TBL] [Abstract][Full Text] [Related]
4. Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy.
Ji Y; Sy SKB
Cancer Chemother Pharmacol; 2024 Apr; 93(4):273-293. PubMed ID: 38430307
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
Peskov K; Azarov I; Chu L; Voronova V; Kosinsky Y; Helmlinger G
Front Immunol; 2019; 10():924. PubMed ID: 31134058
[TBL] [Abstract][Full Text] [Related]
6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
7. A risk stratification model for toxicities in phase 1 immunotherapy trials.
Hernando-Calvo A; Salawu A; Chen RY; Araujo DV; Oliva M; Liu ZA; Siu LL
Eur J Cancer; 2022 Nov; 175():11-18. PubMed ID: 36084619
[TBL] [Abstract][Full Text] [Related]
8. Rational design and identification of immuno-oncology drug combinations.
Iafolla MAJ; Selby H; Warner K; Ohashi PS; Haibe-Kains B; Siu LL
Eur J Cancer; 2018 May; 95():38-51. PubMed ID: 29631102
[TBL] [Abstract][Full Text] [Related]
9. Lights and Shadows in Immuno-Oncology Drug Development.
Bergamino Sirvén M; Pernas S; Cheang MCU
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572060
[TBL] [Abstract][Full Text] [Related]
10. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Anagnostou V; Yarchoan M; Hansen AR; Wang H; Verde F; Sharon E; Collyar D; Chow LQM; Forde PM
Clin Cancer Res; 2017 Sep; 23(17):4959-4969. PubMed ID: 28864724
[TBL] [Abstract][Full Text] [Related]
11. Evolving or immutable - phase I solid tumor trials in the era of precision oncology.
Stockton SS; Ayers GD; Lee C; Laferriere H; Das S; Berlin J
Invest New Drugs; 2024 Jun; 42(3):326-334. PubMed ID: 38775890
[TBL] [Abstract][Full Text] [Related]
12. Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.
Marous M; Bièche I; Paoletti X; Alt M; Razak AR; Stathis A; Kamal M; Le Tourneau C
Ann Oncol; 2015 Dec; 26(12):2419-28. PubMed ID: 26371283
[TBL] [Abstract][Full Text] [Related]
13. Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early-phase oncology trials.
Freeman GA; Kimmelman J
Clin Cancer Res; 2012 Dec; 18(23):6478-84. PubMed ID: 22912391
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic modelling of biomarker data in oncology.
Jackson RC
ISRN Pharmacol; 2012; 2012():590626. PubMed ID: 22523699
[TBL] [Abstract][Full Text] [Related]
15. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
Parker JL; Kuzulugil SS; Pereverzev K; Mac S; Lopes G; Shah Z; Weerasinghe A; Rubinger D; Falconi A; Bener A; Caglayan B; Tangri R; Mitsakakis N
Cancer Med; 2021 Mar; 10(6):1955-1963. PubMed ID: 33620160
[TBL] [Abstract][Full Text] [Related]
16. Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds.
Radanovic I; Klarenbeek N; Rissmann R; Groeneveld GJ; van Brummelen EMJ; Moerland M; Bosch JJ
Front Oncol; 2022; 12():954806. PubMed ID: 36106110
[TBL] [Abstract][Full Text] [Related]
17. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
Workman P; Aboagye EO; Chung YL; Griffiths JR; Hart R; Leach MO; Maxwell RJ; McSheehy PM; Price PM; Zweit J;
J Natl Cancer Inst; 2006 May; 98(9):580-98. PubMed ID: 16670384
[TBL] [Abstract][Full Text] [Related]
18. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
19. Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.
Freeman GA; Kimmelman J; Dancey J; Monzon JG
Br J Cancer; 2013 Aug; 109(4):897-908. PubMed ID: 23887602
[TBL] [Abstract][Full Text] [Related]
20. Design and reporting of phase III oncology trials with prospective biomarker validation.
Liang F; Peng L; Wu Z; Giamas G; Stebbing J
J Natl Cancer Inst; 2023 Feb; 115(2):174-180. PubMed ID: 36448689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
